More recent research has linked ICOS to the functional advantage of CD8+ antigen-specific T-cell clones isolated from melanoma patients through activation of AKT in the absence of CD28 (Figure 1B) [59], suggesting a potential role in cancer immunotherapy. This evidence concerns the gene CD8A and melanoma.